Background: ST is a treatment modality widely used in LAFLSCC. Although ICT with TPF (docetaxel-Cisplatin-5FU) and CCRT with 3- weekly Cisplatin have been proved as the most active regimens, unfit patients (p) often cannot receive them. There are few data about efficacy of modified ST regimens in unselected population. Methods: From 1998 to 2013, data from LAFLSCC patients treated in our institution with ST were retrospectively reviewed. Patient and treatment-related prognostic factors (PFs) were collected. Both uni and multivariate proportional hazards were used to determine associations with overall survival (OS) and DFS (disease-free survival). Local Ethical Committee approval was obtained. Results: 337 consecutive patients were treated with ST with ICT and CCRT. Median age: 57 years. Male:92%. Stage: 135 p III (40.1%), 202p IV (59.9%). Median follow-up: 38.9 m (0- 222 m). Median OS: 48,3m (95%CI 36-60). Median DFS: 105,3 m (95%CI 90-120). Analyzed tumor-related PFs: location, stage, differentiation. Patient-related PFs: age, blood cells ratios (NLR, dNLR, LMR), ACE-27 comorbidity index, Hemoglobin, albumin. Treatment-related PFs: ICT type , CCTR type, ICT response. In Multivariate analysis (MA) several PFs independently correlated with OS and DFS (Table 1). Use of TPF as ICT was independently linked to better OS and DFS. Use of 3-weekly Cisplatin as CCRT was associated with better OS. Conclusions: In unselected LALFSCC patients treated with ST, selection of proved efficacious therapies affects outcome, independently of other tumor and patient-related PFs. Suboptimal regimens work worse. In unfit patients other alternatives should be considered.